文献速递糖尿病

白细胞介素-22治疗对NOD小鼠自身免疫性糖尿病的影响

The effect of interleukin-22 treatment on autoimmune diabetes in the NOD mouse.
PubMed 文献 · Diabetologia · 2017-08-04

研究在6周龄NOD小鼠中每两周腹腔注射重组小鼠IL-22(200 ng/g)或PBS,至连续两次非空腹血糖≥11 mmol/l诊断显性糖尿病;对照组确诊后用LinBit胰岛素植入片并随机给予PBS或IL-22治疗。结果显示IL-22未延迟糖尿病发生,也未改善胰岛面积、血糖控制、β细胞残余功能、内质网应激、胰岛炎或巨噬细胞与中性粒细胞浸润。

要点

  • IL-22治疗未延迟NOD小鼠显性糖尿病的发生。
  • IL-22未改善胰岛面积、血糖控制、β细胞残余功能或内质网应激。
  • 治疗性IL-22未降低循环脂多糖,未延长蜜月期。

核心结论

  • 研究提示,在该给药方案下,无论于显性糖尿病前还是确诊时给予重组小鼠IL-22,均不能预防NOD小鼠自身免疫性糖尿病或延长蜜月期。

研究设计与样本

  • 6周龄NOD小鼠每两周腹腔注射重组小鼠IL-22(200 ng/g)或PBS(溶剂对照),直至连续两次非空腹血糖≥11 mmol/l诊断显性糖尿病。
  • 对照组确诊后接受LinBit胰岛素植入片,并随机接受每两周PBS或IL-22(200 ng/g)治疗,随访至上述标准诊断显性糖尿病。

主要发现

  • 与溶剂对照小鼠相比,IL-22治疗未延迟糖尿病发生。
  • 未观察到胰岛面积、血糖控制、β细胞残余功能、内质网应激、胰岛炎或巨噬细胞和中性粒细胞浸润改善,依据为非空腹血糖、C肽和组织学评分。
  • 治疗性给予IL-22未降低循环脂多糖(肠道黏膜完整性受损的标志物)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The aim of this study was to determine whether therapy with the cytokine IL-22 could be used to prevent the development of, or treat, autoimmune diabetes in the NOD mouse. METHODS: Six-week-old NOD mice were administered bi-weekly either recombinant mouse IL-22 (200 ng/g) or PBS (vehicle control) intraperitoneally until overt diabetes was diagnosed as two consecutive measurements of non-fasting blood glucose ≥ 11 mmol/l. At this time, NOD mice in the control arm were treated with LinBit insulin pellets and randomised to bi-weekly therapeutic injections of either PBS or IL-22 (200 ng/g) and followed until overt diabetes was diagnosed, as defined above. RESULTS: IL-22 therapy did not delay the onset of diabetes in comparison with the vehicle-treated mice. We did not observe an improvement in islet area, glycaemic control, beta cell residual function, endoplasmic reticulum stress, insulitis or macrophage and neutrophil infiltration as determined by non-fasting blood glucose, C-peptide and histological scoring. Therapeutic administration of IL-22 did not reduce circulating lipopolysaccharide, a marker of impaired gut mucosal integrity. CONCLUSIONS/INTERPRETATION: Our study suggests that, at this dosing regimen introduced either prior to overt diabetes or at diagnosis of diabetes, recombinant mouse IL-22 therapy cannot prevent autoimmune diabetes, or prolong the honeymoon period in the NOD mouse.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Borg DJ, Wang R, Murray L, et al. The effect of interleukin-22 treatment on autoimmune diabetes in the NOD mouse. Diabetologia. 2017. PMID: 28779211. doi:10.1007/s00125-017-4392-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。